Ran Nussbaum

Ran is a managing partner and co-founder of The Pontifax Group. The fund runs more than 50 portfolio companies around the Globe. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. In the past Ran served on Kite pharma BOD (sold to Gilead), cCAM Therapeutics (sold to Merck), and ArQule (ARQL) (sold to Merck) . he also chaired Ocon Medical, Nasvax, Spearhead and Biomedix. Currently, Ran sits on many of Pontifax’s portfolio companies including Eloxx Therapeutics (ELOX), UroGen (URGN), and Prevail Therapeutics. Ran also serves as Keros’ chairman of the board.